News | March 08, 2022
Industry upbeat on biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Clinical trial supply company strengthens its presence in the European Union
100% efficacy against severe Covid-19 disease and hospitalizations
The facility will manufacture its Herceptin biosimilar, Tuznue
Subscribe To Our Newsletter & Stay Updated
